Novartis: new positive data for Kisqali

(CercleFinance.com) - On Monday Novartis unveiled new data for Kisqali at the ESMO Cancer Congress in Berlin.


According to the findings, the drug increased overall survival in postmenopausal women with advanced or metastatic HR+/HER2- breast cancer by nearly 16 months.

This data - compiled over a five-year period - shows that Kisqali added to fulvestrant as first-line therapy resulted in a median overall survival of nearly five and a half months in treated patients compared to fulvestrant alone.

These additional analyses also showed that patients receiving Kisqali plus fulvestrant had a 28% lower risk of death compared to those receiving fulvestrant alone.

Kisqali helps slow cancer progression by inhibiting two proteins that, when overactivated, can cause cancer cells to grow and divide rapidly.

Little impact though - the share is currently down 0.5% in Zurich.


Copyright (c) 2022 CercleFinance.com. All rights reserved.